Clinical Trial Update: Pediatric Expanded Access Program-Oral Solution (0831-908) [Phase 3]

View source ↗

Summary

This document reports the completion of a pediatric expanded access program for an oral solution (0831-908) sponsored by Merck for HIV infections.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Oral Solution 0831-908

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV Infections | Phase 3 | Status: COMPLETED